LN229 Cells
CAD$545.10*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | LN229 is a human glioblastoma cell line derived from a 60-year-old White female patient with glioblastoma multiforme (GBM), specifically from the right frontal parieto-occipital cortex. Glioblastoma is one of the most aggressive and lethal forms of brain cancer, and LN229 cells are extensively used in research to understand the disease's molecular underpinnings and to develop potential therapeutic strategies. The cells display an epithelial-like morphology and exhibit adherent growth properties, which makes them ideal for in vitro studies. Given their high tumorigenic potential, they readily form tumors when injected into nude mice, making them a robust model for cancer research. One of the critical characteristics of LN229 cells is the presence of a mutated p53 gene (TP53), with a specific CCT (Pro) to CTT (Leu) mutation at codon 98. This mutation contributes significantly to the cell line's aggressive behavior and resistance to apoptosis. Additionally, LN229 cells have a wild-type PTEN gene, but they exhibit homozygous deletions in the p16 and p14ARF tumor suppressor genes, which are vital regulators of the cell cycle and apoptosis. These genetic alterations make LN229 a valuable model for studying the impact of these mutations on tumor biology and therapeutic resistance. LN229 cells are particularly useful in apoptosis studies. They undergo apoptosis upon stimulation with Fas ligand, with cell death occurring within 16 hours. Interestingly, while Bcl-2 expression can protect LN229 cells from Fas ligand-induced apoptosis, it only offers limited protection against apoptosis induced by puromycin, a protein synthesis inhibitor. This selective resistance pattern makes LN229 cells a critical model for understanding the molecular mechanisms of apoptosis in glioblastoma and for testing potential apoptosis-modulating therapies. As with all in vitro research models, LN229 cells are not suitable for therapeutic or in vivo applications. |
|---|---|
| Organism | Human |
| Tissue | Brain, right frontal parieto-occipital cortex |
| Disease | Glioblastoma |
| Synonyms | LN 229, LN229, LNT-229 |
Characteristics
| Age | 60 years |
|---|---|
| Gender | Female |
| Ethnicity | European |
| Morphology | Epithelial |
| Growth properties | Adherent |
Regulatory Data
| Citation | LN229 (Cytion catalog number 305043) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_0393 |
Biomolecular Data
Handling
| Culture Medium | DMEM, w: 4.5 g/L Glucose, w: 4 mM L-Glutamine, w: 3.7 g/L NaHCO3, w: 1.0 mM Sodium pyruvate (Cytion article number 820300a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Dissociation Reagent | Accutase |
| Doubling time | 31 hours |
| Subculturing | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
| Fluid renewal | 2 to 3 times per week |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305043-010823 | Certificate of Analysis | 23. May. 2025 | 305043 |
-
Required products
Required products
Antibiotic/Antimycotic Solution (100x)Product Overview
Volume: 100 ml
Storage: ≤-15°C
Sterility: Sterile-filtered
Antibiotic/Antimycotic Solution (100x) is a sterile, ready-to-use concentrate designed to reduce microbial contamination risks in cell culture and related laboratory applications. This 100x solution contains a well-established combination of penicillin, streptomycin, and amphotericin B—providing broad-spectrum antimicrobial activity against Gram-positive and Gram-negative bacteria, yeasts, and filamentous fungi. The formulation is suitable for use in eukaryotic cell cultures, bacterial media, and other contamination-sensitive systems, supporting clean and consistent lab operations.
Application and Benefits Optimized for routine research protocols, this solution is widely used to maintain aseptic conditions in cell culture workflows. It offers reliable performance in contamination-sensitive environments, helping researchers reduce the risk of microbial overgrowth without compromising cell health or experimental reproducibility. The sterile-filtered formulation eliminates the need for additional solubilization steps, supporting streamlined media preparation and reducing variability in daily lab procedures.
Usage and Compatibility To achieve standard working concentrations, dilute the solution 1:100 into your complete culture medium. The product is compatible with a broad range of mammalian cell lines and basal media. With consistent stock availability, researchers benefit from dependable supply continuity and simplified logistics planning. The solution should be stored at ≤ –15 °C and protected from repeated freeze-thaw cycles to maintain stability. For research use only. Not for use in diagnostic or therapeutic procedures. Not for use in humans or animals.CAD$62.10*